Scale-invariant biomarker discovery in urine and plasma metabolite
  fingerprints by Zacharias, Helena U. et al.
Scale-invariant biomarker discovery in urine and plasma metabolite
fingerprints
Helena U. Zacharias1a,*, Thorsten Rehbergb,*, Sebastian Mehrlb, Daniel Richtmannc, Tilo
Wettigc, Peter J. Oefnera, Rainer Spangb, Wolfram Gronwald2a and Michael Altenbuchinger3b
aInstitute of Functional Genomics, University of Regensburg, Regensburg, Germany
bStatistical Bioinformatics, Institute of Functional Genomics, University of Regensburg,
Regensburg, Germany
cDepartment of Physics, University of Regensburg, Regensburg, Germany
*The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
Abstract
Motivation: Metabolomics data is typically scaled to
a common reference like a constant volume of body fluid,
a constant creatinine level, or a constant area under the
spectrum. Such normalization of the data, however, may
affect the selection of biomarkers and the biological inter-
pretation of results in unforeseen ways.
Results: First, we study how the outcome of hypoth-
esis tests for differential metabolite concentration is af-
fected by the choice of scale. Furthermore, we observe
this interdependence also for different classification ap-
proaches. Second, to overcome this problem and estab-
lish a scale-invariant biomarker discovery algorithm, we
extend linear zero-sum regression to the logistic regres-
sion framework and show in two applications to 1H NMR-
based metabolomics data how this approach overcomes
the scaling problem.
Availability: Logistic zero-sum regression is avail-
able as an R package as well as a high-performance
computing implementation that can be downloaded at
https://github.com/rehbergT/zeroSum.
1 Introduction
Metabolomics is the comprehensive study of all
small organic compounds in a biological specimen
[German et al. 2005]. Metabolite concentrations in
body fluids such as urine, serum, and plasma have
proven valuable in predicting disease onset and progres-
sion [Dawiskiba et al. 2014, Gronwald et al. 2011,
Zacharias et al. 2013a, Zacharias et al. 2015,
Elliott et al. 2015]. Metabolomic data can be generated
by a variety of methods of which mass spectrometry and
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3michael.altenbuchinger@ukr.de
1H NMR spectroscopy are the most common. While its
high sensitivity makes mass spectrometry the preferred
method for discovery projects, the high reproducibility
of NMR data [Keun et al. 2002] is ideal for applications
in precision medicine.
1H NMR allows for the simultaneous detection of all
proton-containing metabolites present at sufficient con-
centrations in biological specimens. Furthermore, NMR
signal volume scales linearly with concentration. The
complete set of NMR signals acquired from a given
specimen is called its metabolite “fingerprint”. Due
to differences in pH, salt concentration, and/or tem-
perature, relative displacement of signal positions oc-
curs across spectra. Binning schemes can compen-
sate for this effect by splitting spectra into segments
called bins and summing up signal volumes contained
therein. Equal-sized bins are commonly used, albeit other
schemes such as adaptive binning have been suggested
[De Meyer et al. 2008, Anderson et al. 2011]. Binned
fingerprint data is the typical starting point for sub-
sequent multivariate data analysis including biomarker
discovery and specimen classification using methods
such as Support Vector Machines [Cortes et al. 1995,
Burges et al. 1998], ridge [Hoerl et al. 1970], and LASSO
regression [Tibshirani 1996].
Metabolite fingerprints need to be scaled to a common
unit. Typical examples include mmol metabolite per ml
plasma, mmol metabolite per mmol creatinine in urine,
or the relative contribution of a bucket to the total spec-
tral intensity of an NMR spectrum. In practice this is
achieved by dividing each spectrum by the unit defin-
ing quantity: the intensity of an NMR reference such as
TSP, the intensity of creatinine, or the total spectral in-
tensity. This scaling of the raw data defines the measure-
ment, but it also serves a second purpose: scaling corrects
for unwanted experimental and physiological variability in
the raw spectra. Correcting unwanted variability is usu-
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ally called normalization. Instrument performance can
vary and so can patient-specific parameters like the fluid
balance, which is affected by drinking, respiration, defe-
cation, perspiration, or medication, thus altering urine
metabolite concentrations without reflecting disease state
[Ryan et al. 2011, Craig et al. 2006].
All scales have their pros and cons: the NMR
reference can normalize for spectrometer performance
[Viant et al. 2005] but not for unwanted variability in
urine density. Choosing creatinine as a standard for
urine assumes the absence of inter-individual differ-
ences in the production and renal excretion of creati-
nine [Waikar et al. 2010]. In fact, creatinine produc-
tion and excretion is affected by sex, age, muscle mass,
diet, pregnancy, and, most importantly, renal pathology
[Stevens et al. 2009, Curhan 2005]. Normalization to a
constant total spectral intensity or spectral mapping to
a reference spectrum assume that the total amount of
metabolites is constant over time and across patients and
that spectra are not contaminated by signals that do not
represent metabolites. However, this is not always the
case [Hochrein et al. 2015, Ross et al. 2007]. In fact, for
urinary specimens of patients suffering from proteinuria
the additional protein signals greatly increase total spec-
tral area, and scaling to a constant total intensity sys-
tematically underestimates metabolite abundances. Sim-
ilarly, excessive glucose uptake, for example by a glu-
cose infusion, leads to high total spectral intensities that
are dominated by glucose and its metabolites. While
the high values for these metabolites correctly reflect the
metabolic state for these patients, their influence on the
total spectral intensity leads to systematic underestima-
tion of metabolites not related to glucose metabolism.
In general, the preferred scaling protocol depends on
the specific data set to be investigated. However, for some
data sets it is not possible to use the same scale for all
patients in the cohort. We will describe such data sets
below. In this case different protocols need to be used
for different patients, introducing new challenges to data
analysis.
In this contribution, we first studied how the choice of
scale affects statistical analysis, the selection of biomark-
ers, and patients’ diagnosis by these biomarkers. We re-
port on two supervised metabolomics data analysis sce-
narios, namely urine and plasma biomarker discovery in
1D 1H NMR metabolite fingerprints for the early detec-
tion of acute kidney injury onset after cardiac surgery
[Zacharias et al. 2013a, Zacharias et al. 2015]. In both
applications we tested metabolites for differential abun-
dance using alternative scaling protocols. We observed
pronounced disagreements between the lists of signifi-
cantly differential metabolites depending on how the same
data was scaled. More importantly, the different scalings
led to inconsistencies in the classification of individual
patients. In view of these observations, reproducibility of
metabolic studies is only possible if the exact same scaling
protocols are used.
To overcome this problem, we extended zero-sum
regression [Lin et al. 2014, Altenbuchinger et al. 2016],
which has recently been demonstrated to be invariant
under any rescaling of data [Altenbuchinger et al. 2016],
to logistic zero-sum regression and compared it to two
standard methods for constructing multivariate signa-
tures: LASSO logistic regression and Support Vector Ma-
chines in combination with t-score based feature filter-
ing. Unlike the latter methods, logistic zero-sum regres-
sion always identifies the same biomarkers regardless of
the scaling method. Consequently, prior data normaliza-
tion may be omitted completely. We make logistic zero-
sum regression available as an R package and as a high-
performance computing software that can be downloaded
at https://github.com/rehbergT/zeroSum.
2 Experimental Section
2.1 Data Sets
The first data set comprised 1D 1H NMR fingerprints of
n = 106 urine specimens, which had been collected from
patients 24 h after cardiac surgery with cardiopulmonary
bypass (CPB) use at the University Clinic of Erlangen
[Zacharias et al. 2013a]. Of these 106, 34 were diagnosed
with acute kidney injury (AKI) 48 h after surgery. The
challenge in this data is to define a urinary biomarker
signature that allows for the early detection of AKI on-
set (Acute Kidney Injury Network (AKIN) stages 1 to 3).
The second data set consisted of 85 EDTA-plasma speci-
mens, which had been collected 24 h post-op from a sub-
cohort of the original cohort of 106 patients undergoing
cardiac surgery with CPB use and which had been sub-
jected to 10 kDa cutoff filtration [Zacharias et al. 2015].
In total, 33 patients out of these 85 patients were di-
agnosed with postoperative AKI [Zacharias et al. 2015].
Again our goal is to detect biomarkers for an earlier de-
tection of AKI.
2.2 NMR Spectroscopy
A total of 400 µl of urine or EDTA-plasma ultrafil-
trate was mixed with 200 µl of phosphate buffer, pH
7.4, and 50 µl of 0.75% (w) 3-trimethylsilyl-2,2,3,3-
tetradeuteropropionate (TSP) dissolved in deuterium ox-
ide as the internal standard (Sigma-Aldrich, Taufkirchen,
Germany). NMR experiments were carried out on a
600 MHz Bruker Avance III (Bruker BioSpin GmbH,
Rheinstetten, Germany) employing a triple resonance
(1H, 13C, 31P, 2H lock) cryogenic probe equipped with
z-gradients and an automatic cooled sample changer.
For each sample, a 1D 1H NMR spectrum was ac-
quired employing a 1D nuclear Overhauser enhance-
ment spectroscopy (NOESY) pulse sequence with sol-
vent signal suppression by presaturation during relax-
2
ation and mixing time following established protocols
[Zacharias et al. 2013b, Gronwald et al. 2008]. NMR sig-
nals were identified by comparison with reference spectra
of pure compounds acquired under equal experimental
conditions [Zacharias et al. 2013b].
2.3 Data extraction
The spectral region from 9.5 to −0.5 ppm of the 1D spec-
tra was exported as even bins of 0.001 ppm width employ-
ing Amix 3.9.13 (Bruker BioSpin). The data matrix was
imported into the statistical analysis software R version
3.3.2. For the urinary spectra, the region 6.5 – 4.5 ppm,
which contains the broad urea and water signals, was ex-
cluded prior to further analysis. For plasma spectra, the
region 6.2 – 4.6 ppm, containing the urea and remaining
water signals, was removed prior to analysis. In addition,
the regions 3.82 – 3.76 ppm, 3.68 – 3.52 ppm, 3.23 – 3.2
ppm, and 0.75 – 0.72 ppm, corresponding to filter residues
and free EDTA, were excluded prior to classification for
the plasma specimens.
2.4 Scaling and normalization
We compare our scaling- and normalization-invariant ap-
proach to standard analysis strategies that were applied
to data preprocessed by four state-of-the-art normaliza-
tion protocols. For creatinine normalization of urinary
data we divided each bucket intensity by the summed in-
tensities of the creatinine reference region ranging from
3.055 to 3.013 ppm of the corresponding NMR spec-
trum. When scaling to the total spectral intensity we
summed over all signal intensities from 9.5 to 0.5 ppm
after exclusion of the water and urea signals and di-
vided each bucket intensity by this sum. When scaling
to the signal intensity of the NMR reference compound,
in our case TSP, we summed up the intensities of the
TSP buckets ranging from −0.025 to 0.025 ppm and di-
vided each bucket intensity by this sum. This normaliza-
tion method corrects for differences in spectrometer per-
formance [Zacharias et al. 2015], but not for differences
in fluid intake. Finally, we also evaluated Probabilis-
tic Quotient Normalization (PQN) [Dieterle et al. 2006].
PQN follows the rationale that changes in concentra-
tion of one or a few metabolites affect only small seg-
ments of the spectra, whereas specimen dilution, for ex-
ample due to differences in fluid intake in case of urinary
specimens, influences all spectral signals simultaneously
[Dieterle et al. 2006]. Following [Dieterle et al. 2006] we
first normalized each spectrum to its total spectral inten-
sity. Then, we took the median across all these spectra
as the reference spectrum and calculated the ratio of all
bucket intensities between raw and reference spectra. The
median of these ratios in a sample was our final division
factor.
For subsequent analysis, only the spectral region be-
tween 9.5 and 0.5 ppm was taken into account. To com-
pensate for slight shifts in signal positions across spectra
due to small variations in sample pH, salt concentration,
and/or temperature, bucket intensities across ten buck-
ets were fused together in one bucket of 0.01 ppm width
by summing up the individual bucket intensities. The
resulting intensities were log 2 transformed to correct for
heteroscedasticity, and all subsequent data analysis was
performed with these values.
2.5 Classification algorithms
We compared logistic zero-sum regression to two classifi-
cation algorithms for normalized data, namely a Support
Vector Machine [Cortes et al. 1995] employing a linear
kernel function combined with univariate feature filtering
(f-SVM) and the least absolute shrinkage and selection
operator (LASSO) logistic regression [Tibshirani 1996].
In the LASSO logistic regression and the zero-sum mod-
els, the penalizing parameter λ that balances the bias
variance trade-off was optimized in an internal cross-
validation. LASSO models were trained utilizing the
R package glmnet [Friedman et al. 2010]. The zero-sum
models were trained by employing our zeroSum software,
which is implemented in two versions: first, a version
optimized for high-performance computing (HPC), and
second, an R package for ordinary desktop computers.
We utilized the zeroSum HPC implementation through-
out the article.
The parameter λ induces sparseness of the models and
circumvents over-fitting for LASSO and zero-sum mod-
els. Similarly, we optimized the parameters of f-SVM.
This was done in a two-fold nested cross-validation, i.e.,
in each cross-validation step we screened for the best
feature threshold, allowing for {21, 22, 23, 24, 25, 26} in-
cluded features, and the matching best cost parame-
ter, which was screened in {2−5, 2−4, . . . , 24, 25}. For
training the SVM we utilized the R package e1071
[Dimitriadou et al. 2011].
3 Results
3.1 Stand-alone biomarker discovery de-
pends on the choice of scale
Metabolic biomarkers can be metabolites or just spectral
features. Moreover, they can be identified as stand-alone
predictors or as part of a multivariate biomarker signa-
ture. Before we focus on signatures we study the effect
of scales on stand-alone biomarkers. More precisely, we
focus on spectral buckets with differential intensities be-
tween two classes of samples, i.e., from patients who de-
veloped acute kidney injury after cardiac surgery versus
from those that did not.
Bin intensities were normalized to (a) a constant total
spectral intensity, (b) a constant creatinine intensity, (c) a
median reference spectrum employing the most probable
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Figure 1: − log10(p-values) of moderated t-test analysis comparing healthy versus diseased patients for the urinary
AKI data set after preprocessing with four different normalization methods, i.e., scaling to (a) equal total spectral
area, (b) scaling to creatinine, (c) PQN, and (d) scaling to TSP, respectively, plotted versus the ppm regions of the
corresponding NMR features (upper figure). A red line marks the significance level for Benjamini-Hochberg (B/H)
adjusted p-values below 0.01, corresponding to a false discovery rate (FDR) below 1%. All NMR features with a
B/H-adjusted p-value below 0.01 are represented as red dots. The lower figures, (e - h), show the corresponding log 2
fold changes (log 2 FC) versus the ppm regions of the corresponding NMR features. log 2 FCs were calculated as AKI
minus non-AKI, thus positive log 2 FCs correspond to higher values in AKI than in non-AKI.
quotient and (d) a constant intensity of the NMR refer-
ence. For scoring normalized bin intensities as potential
biomarkers we used Benjamini-Hochberg (B/H) corrected
p-values from the moderated t-statistics implemented in
the R package LIMMA [Ritchie et al. 2015] and log 2 fold
changes between the classes.
Figure 1 shows plots of spectral bin positions against
− log 10(p-values) (a-d) and log 2 fold changes (e-h) be-
tween AKI and non-AKI urine specimens. From left to
right the plots correspond to (a,e) normalization by total
spectral intensity, (b,f) normalization to creatinine, (c,g)
PQN, and (d,h) normalization to TSP. The red line in
plots (a-d) marks a significance level of 0.01, correspond-
ing to a false discovery rate (FDR) below 1%. Significant
buckets are plotted in red in all eight plots.
Normalization to total spectral intensity: On this
scale we observed almost exclusively negative fold changes
indicating lower bucket intensities for AKI in comparison
to non-AKI. 242 features were significant with features
corresponding to carnitine, 2-oxoglutaric acid, and glu-
tamine ranking highest. Supplementary Table S1 (a) lists
raw and B/H-adjusted p-values as well as metabolite as-
signments of the top ten significant buckets.
Technical artifacts of the scale become apparent too:
the spectral region from 4 to 3.5 ppm, highlighted as
a blue band, hardly comprised any significant features.
This region is dominated by signals from sugars such as D-
mannitol, which had been used as a pre-filling material for
the tubes of the CPB machine [Zacharias et al. 2013a].
As D-mannitol exhibits a rather large number of NMR
signals, as highlighted in an exemplary urine spectrum
shown in Figure 2, it comprised between 15% and 82%
of the total spectral areas. On a scale that makes the
total spectral area the same across all samples these sig-
nals cannot serve as biomarkers. However, all patients
take up D-mannitol during surgery, and the amount of
D-mannitol still found in urine 24 h past surgery is mod-
ulated by actual kidney function. D-mannitol entangles
kidney function with the total spectral area. Therefore,
the spectral area can not be recommended for scaling
biomarkers, at least not in this context.
Normalization to creatinine: For this scale we ob-
served different analysis results. log 2 fold changes were
predominantly positive indicating higher metabolite lev-
els in AKI patients. 204 buckets were significant, and the
top ten are listed in Supplementary Table S1 (b). The
biomarker ranked highest was tranexamic acid, which is
given in cardiac surgery to prevent excessive blood loss.
Strikingly, the region between 4 and 3.5 ppm (blue band)
containing the D-mannitol signals was highly significant
on this scale.
However, this scale confounds with aspects of kidney
function. In response to kidney disease urinary creati-
nine excretion rates can be affected [Waikar et al. 2010].
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Thus, normalization to creatinine can also obscure other
metabolite biomarkers if their excretion correlates with
that of creatinine.
Probabilistic Quotient Normalization: On this
scale we observed both positive and negative fold changes
in almost equal numbers. Only 89 features were now sig-
nificant, and the top ten are listed in Table S1 (c), with
carnitine and glutamine as the leading biomarkers. Again,
the blue shaded region now covers significant features, al-
though the number is much lower than after creatinine
scaling.
Due to the strong conceptual similarity between PQN
and normalization to total spectral intensity, the D-
mannitol artifact also compromises the use of PQN.
TSP normalization: On this scale we did not detect
any significant biomarkers. The scaling method corrects
only for differences in spectrometer performance, not for
changes in global metabolite concentration. Due to large
variability in urine density throughout the cohort, it can
not be used in this context.
We observed only one bucket at 3.715 ppm, identified
as an overlap of propofol-glucuronide, broad protein sig-
nals, and tentatively D-glucuronic acid, which obtained a
significant p-value on three scales (Figure 3a).
The plasma data biomarker discovery was not consis-
tent across scales either (Supplementary Table S2, Fig-
ure S1, and Figure 3b). Scaling to total spectral area
and scaling to TSP predominantly identified metabo-
lites that accumulate in the blood of patients develop-
ing AKI. One might explain this observation by a re-
duced glomerular filtration in these patients. However,
the PQN data immediately challenged this interpretation,
as it identified a large set of down-regulated metabolites in
AKI. Creatinine normalization is not common for plasma
metabolomics and was not investigated here.
Figure 2: Exemplary 1D 1H NMR spectrum of a urine
specimen collected 24 h after surgery from an AKI pa-
tient. The lower histogram illustrates the common bin-
ning procedure.
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Figure 3: Number of significant buckets and their overlap
between the different scaling methods for (a) the AKI
urine and (b) the AKI plasma data set.
3.2 Multivariate biomarker signatures
can be scale dependent
Biomarkers can be combined to biomarker signatures in
multivariate analysis. Machine-learning algorithms are
used to learn these signatures from training data. We
tested two of these algorithms, namely a linear SVM with
t-score based feature filtering (f-SVM) and standard lo-
gistic LASSO regression. Both methods implement linear
signatures of the form
β0 +
p∑
j=1
βj log2(ΓiXij), (1)
where Xij is the raw signal from bucket j in patient i,
βj the weight of this feature, and Γi the scaling factor
used to normalize sample i. Both methods were used to
learn signatures from data normalized in four different
ways, namely scaling by total spectral area, scaling to
creatinine, PQN, and scaling to TSP. The performance of
the algorithms was tested in cross-validation.
Figure 4a shows ROC curves of signatures that aim to
predict AKI from urinary fingerprints using f-SVM signa-
tures. The areas under the ROC curves (AUC-ROC) are
summarized in Table 1. The higher this area the better
the prediction of patient outcome. Performances ranged
from an AUC of 0.72 for TSP-scaled data to an AUC of
0.83 for PQN data. In line with the results for stand-alone
biomarkers, the f-SVM algorithm picked different features
across scaling methods. Not a single bucket was chosen
simultaneously for all four scales (Figure 4a bottom row).
Figure 4b and Table 1 show the corresponding results for
standard LASSO logistic regression. The LASSO signa-
tures performed slightly better and were more consistent.
Nevertheless, there is still a dependence of the chosen
biomarkers on the scale. Similar results were observed
for the plasma data set (Supplementary Figure S2).
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Table 1: AUC-ROC values of three different classifica-
tion approaches, f-SVM, LASSO logistic regression, and
zero-sum regression after application of four different nor-
malization methods, i.e., scaling to total spectral area,
scaling to creatinine, Probabilistic Quotient Normaliza-
tion (PQN), and scaling to TSP, for the (a) urinary AKI
and (b) plasma AKI data set.
(a) Urinary AKI data set
Normalization f-SVM LASSO Zero-sum
method logistic regr. logistic regr.
Tot. spec. area 0.80 0.81 0.83
Creatinine 0.77 0.81 0.83
PQN 0.83 0.85 0.83
TSP 0.72 0.79 0.83
(b) Plasma AKI data set
Normalization f-SVM LASSO Zero-sum
method logistic regr. logistic regr.
Tot. spec. area 0.85 0.84 0.89
PQN 0.84 0.86 0.89
TSP 0.87 0.84 0.89
3.3 For standard methods prediction of
patient outcome is scale dependent
From a clinical perspective, varying biomarkers constitute
only a minor problem, as long as they agree in their pre-
dictions of outcome. However, they usually do not agree.
For the urinary data set, LASSO signatures yielded con-
flicting predictions in 16% of patients. For f-SVM signa-
tures, the percentage increased to 30%.
Figure 5 summarizes the predictions of AKI onset after
cardiac surgery patient by patient for the urinary data set.
The row “patient outcome” shows patients in blue who did
not develop AKI (AKIN stage 0) and in red those that de-
veloped AKI. Furthermore, the yellow dashed lines high-
light patients with AKIN stage 2 and 3, a more severe
manifestation of kidney injury. The latter patients con-
stitute the high-risk group where early detection of AKI
onset can save lives [Cruz et al. 2009]. The true outcomes
48 h after surgery are contrasted to the predictions 24 h
earlier. Shown are predictions of f-SVM and LASSO sig-
natures for the four scaling methods.
We observed that predictions frequently changed with
scale and that signatures learned on data that was scaled
to, e.g., creatinine did not properly identify the highest
risk group. For f-SVM only the signature on PQN data
identified all high-risk patients correctly. The LASSO
identified high-risk patients for total spectral area and
PQN data correctly.
We discuss some misclassifications in more detail. Pa-
tients AKI-35 and AKI-106 developed severe AKI after
48 h but were not predicted to do so by two of the f-
SVM signatures, namely those for creatinine and total
spectral area scaled data. A key observation of this paper
is that these misclassifications could be traced back to
data normalization. In theory, the predictions could have
been saved by readjusting the scaling of these fingerprints
(however, the necessary scaling factor is not evident a pri-
ori). Figure 6 shows the prediction probabilities of these
f−SVM
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Figure 4: The urinary AKI data set: Receiver operat-
ing characteristic (ROC) curves for two classification ap-
proaches, (a) SVM in combination with t-test based fea-
ture filtering and (b) LASSO, after application of four
different normalization strategies: scaling to total spec-
tral area (red solid line), scaling to creatinine (blue dashed
line), Probabilistic Quotient Normalization (PQN) (green
dotted line), and scaling to TSP (yellow dashed-dotted
line). The bottom row shows the number of features in-
cluded in the respective classification models in Venn dia-
grams. The corresponding models were built by averaging
over all models of the outer CV loop.
signatures on the y-axis. If this probability was above 0.5
we predicted an onset of AKI, otherwise we did not. The
x-axis shows possible multiplicative scale adjustments Γ.
A value of Γ = 1 indicates the actual scale used for pre-
diction. Values of Γ < 1 correspond to a down-scaling
of all buckets by the factor Γ, while values of Γ > 1 cor-
respond to an up-scaling by Γ. The plot thus shows the
probability of developing AKI as a function of the scale-
readjustment factor Γ. The dashed lines correspond to
f-SVM and the solid lines to LASSO signatures. Colors
indicate the underlying scaling methods of the signatures:
total spectral area (red), creatinine (blue), PQN (green),
and TSP (yellow).
On the original scale (Γ = 1) patient AKI-35 shows pre-
diction probabilities below 0.5 for f-SVM-creatinine (blue
dashed line) and f-SVM-total-area (red dashed line). Let
kcrea be the ratio of the creatinine signal (from 3.055 to
3.013 ppm) and the remaining spectral area after exclu-
sion of the D-mannitol region (4.0 to 3.5 ppm). For AKI-
35 we observed kcrea = 0.069, while the median over all
AKI predicted samples was kcrea = 0.036. In line with
this, up-scaling the fingerprint rescues the prediction for
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Figure 5: Classification results patient by patient for the urinary AKI data set: The row “patient outcome” shows
patients that did not develop AKI in blue, patients that developed AKI in red, whereas patients that developed
severe AKI (AKIN stage 2 and 3) are further highlighted by the yellow dashed region. Above we give predictions
for the onset of AKI for f-SVM, LASSO, and zero-sum, using normalization strategies as indicated in brackets. AKI
predictions are shown in red (AKIN stages 1 to 3), while patients predicted as non-AKI are shown in blue. Patients
discussed in subsection 3.3 are indicated by green sample names.
this patient (blue dashed line in Figure 6a). Similarly,
kD-man, the ratio between D-mannitol and the remaining
spectral area, was 2.22, while the median over all AKI pre-
dicted samples was 2.42, which explains why the f-SVM-
total-area prediction could be rescued by a down-scaling
of the fingerprint (red dashed line in Figure 6a). Similar
problems can be observed for patient AKI-106, and for
the LASSO-creatinine signature in patients AKI-70 and
AKI-4.
For the plasma data, we observed inconsistent predic-
tions for 19% (6%) of the patients for f-SVM (LASSO)
(Supplementary Figure S3). Here, no method identified
the high-risk group completely, with best identification
shown for LASSO on PQN data.
In summary, we observed inconsistencies in the selec-
tion of biomarkers and more importantly in the prediction
of patient outcome across the four scaling methods. These
inconsistencies were most pronounced for the filter-based
feature selection in f-SVM and affected urinary finger-
prints more than plasma fingerprints. Still they could be
observed for all analysis scenarios. For several patients a
simple scale adjustment would have saved the prediction.
The next section will show that zero-sum logistic regres-
sion resolves these inconsistencies fully and leads to more
accurate predictions.
3.4 Logistic zero-sum regression
Zero-sum regression [Lin et al. 2014] is a novel machine-
learning algorithm that is insensitive to rescaling the data
[Altenbuchinger et al. 2016]. It allows for a selection of
biomarkers that does not depend on the units chosen. The
classifications of patients that result from these signatures
do not depend on any scaling of the data either. In fact,
patients can be classified with spectral data that were not
normalized at all.
For the reader’s convenience we review the concept here
in a nutshell: Let (xi, yi) be metabolomics data, where xij
is the logarithm of the intensity for bucket j ∈ {1, . . . , p}
in sample i ∈ {1, . . . , N} and yi the corresponding clinical
response of patient i. In regression analysis the data sets
need to be normalized to a common unit. Note that the
data are on a logarithmic scale, therefore the scaling to
a common unit becomes a shifting of the spectrum xi by
some sample specific value γi. Thus for normalized data
the regression equation reads
yi = β0 +
p∑
j=1
βj(xij + γi) + i. (2)
Now note that the equation becomes independent of the
normalization γi if and only if the regression coefficients
βj sum up to zero, i.e.,
p∑
j=1
βj = 0 . (3)
This is the idea of zero-sum regression. In the
machine-learning context of high-content data, zero-sum
regression can be combined with LASSO or elastic-
net regularization and shows predictive performances
that were not compromised by the zero-sum constraint
[Altenbuchinger et al. 2016].
In many biomarker discovery challenges the response y
is not continuous but binary. We thus need to extend the
concept of zero-sum regression from linear regression to
classification. We do this by introducing logistic zero-sum
regression.
In standard logistic regression the log-likelihood of nor-
malized data reads
L0(β0, β) = 1
N
{
N∑
i=1
yi
(
β0 + x˜
T
i β
)
− log
(
eβ0+x˜
T
i β + 1
)}
,
(4)
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Figure 6: The probability of AKI prediction as a function
of the scale readjustment factor Γ (see text). The dashed
lines correspond to f-SVM signatures and the solid lines to
LASSO signatures. Colors indicate the underlying scal-
ing methods of the signatures: total spectral area (red),
creatinine (blue), PQN (green), and TSP (yellow). The
black dotted line gives the zero-sum predictions, which
are independent of Γ.
where we abbreviated x˜ij = xij + γi. In this general-
ized linear model the log-likelihood again becomes inde-
pendent of the normalization γi if the regression coeffi-
cients βj add up to zero. This statement also holds if
we add the penalizing term λPα(β) = λ(α||β||1 + (1 −
α)||β||2), which corresponds to the elastic-net regular-
ization penalty. The parameter λ is calibrated in cross-
validation [Friedman et al. 2010], while α is usually fixed
to a specific value in [0, 1]. Here, α = 0 corresponds
to ridge regression [Hoerl et al. 1970] and α = 1 to the
LASSO [Tibshirani 1996]. Thus, logistic zero-sum regres-
sion amounts to finding coefficients (β0, βj) that minimize
− L0(β0, β) + λPα(β) subject to
p∑
j=1
βj = 0 . (5)
For all applications throughout the article, we have chosen
α = 1.
As proposed by [Friedman et al. 2010] we use the
quadratic approximation of Eq. (4) locally at the cur-
rent parameters (β˜0, β˜) of the optimization algorithm:
l(β0, β) = − 1
2N
N∑
i=1
(
wi
(
zi − β0 − xTi β
)2
+ Ci
)
(6)
with
wi = p˜(xi)(1− p˜(xi)) , (7)
zi = β˜0 + x
T
i β˜ +
yi − p˜(xi)
p˜(xi)(1− p˜(xi)) , (8)
p˜(xi) =
1
1 + e−β˜0−xT β˜
. (9)
Ci is independent of (β0, β) and can thus be neglected.
An efficient coordinate-descent algorithm for zero-sum re-
gression can be constructed by incorporating the zero-sum
constraint into the log-likelihood by substituting βs with
βs = −∑pj=1
j 6=s
βj [Altenbuchinger et al. 2016]. Calculat-
ing the partial derivative of the resulting log-likelihood
with respect to βk (k 6= s) and solving for βk yields an
update scheme for βk and βs:
βˆk =
1
aks
·

bks − λα if βˆk > 0 ∧ βˆs > 0 ,
(bks − 2λα) if βˆk > 0 ∧ βˆs < 0 ,
(bks + 2λα) if βˆk < 0 ∧ βˆs > 0 ,
bks if βˆk < 0 ∧ βˆs < 0 ,
else skip update ,
(10)
aks =
1
N
N∑
i=1
wi(−xik + xis)2 + 2λ(1− α) , (11)
bks =
1
N
N∑
i=1
wi(xik − xis)
·
(
zi − β0 −
P∑
j=1
j 6=s,k
xijβj + xis
p∑
j=1
j 6=s,k
βj
)
− λ(1− α)
p∑
j=1
j 6=s,k
βj . (12)
The update value for βs is given by βs = −∑pj=1
j 6=s
βj . Af-
ter each update the approximation has to be renewed.
Since we update βk and βs simultaneously the number of
updates scales quadratically with the number of features.
Therefore, the minimization problem (5) will be compu-
tationally demanding if x becomes high-dimensional.
3.5 HPC Implementation
We performed a nested cross-validation (CV), where the
inner CV uses 10 folds to determine a suitable regulariza-
tion strength λ and the outer CV is a leave-one-out CV to
evaluate the prediction accuracy of the resulting models.
We are evaluating two different data sets, each within
a leave-one-out CV, one data set with 4 and the other
with 3 different normalizations, and therefore we have
to do 107×4+86×3=686 independent inner CVs. Each
of these CVs is performed on an approximated regular-
ization path of length 500, however, the algorithm stops
8
when overfitting occurs. In total we performed 1,790,855
model fits. This number presents an obvious computa-
tional challenge. To avoid numerical uncertainties in the
feature selection we used the very precise convergence cri-
terion of 10−8, which additionally increases the computa-
tional effort.
On a standard server (2 Intel Xeon X5650 processors
with 6 cores each), the complete calculation took about
two days. We were able to bring the compute time down
to 12 minutes by developing an HPC implementation of
zeroSum and executing it on 174 nodes of the supercom-
puter QPACE 3 operated by the computational particle
physics group.
QPACE 3 currently comprises 352 Intel Xeon Phi 7210
(“Knights Landing”) processors, connected by an Omni-
Path network. Each processor contains 64 compute cores,
and each of these compute cores contains two 512-bit wide
vector units. To run efficiently on this machine, the zero-
Sum C code was extended to use AVX512 vector intrin-
sics for the calculation of the coordinate-descent updates.
OpenMP is used to parallelize the inner CV so that the
data has to be stored in memory only once and can be
accessed from all folds.
Additionally, we provide a new zeroSum R package,
which is a wrapper around the HPC version and can easily
be used within R. This R package also includes functions
for exporting and importing all necessary files for/from
the HPC implementation.
For users without access to HPC facilities, our package
can be run on a regular workstation with reduced conver-
gence precision and a shorter regularization path in less
than one hour.
3.6 Logistic zero-sum regression is scale
independent
Logistic zero-sum regression is not affected by changes
in scale. Actually, it will always yield the same re-
sult regardless of the scaling method used. Figure
7 gives the corresponding ROC curves and Venn dia-
grams for the four normalization strategies investigated.
Since zero-sum models are scale independent, this clas-
sification approach always identified the same biomark-
ers and assigned the same weights to them indepen-
dently of the normalization method chosen. Supple-
mentary file 1 (supplementary file 2) lists all NMR
buckets and corresponding metabolites for the urinary
(plasma) data set with regression weights not equal to
zero in at least one classification-normalization approach.
Again consider the urinary AKI data set. Metabo-
lites with large absolute regression weights (≥ 0.2) in
the zero-sum models included both endo- as well as
exogenous compounds. The largest positive regression
weight was assigned to a bucket at 3.285 ppm, which
was identified as a superposition of myo-inositol, tau-
rine, 4-hydroxy-propofol-4-OH-D-glucuronide, and ten-
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Figure 7: Receiver operating characteristic (ROC) curves
for logistic zero-sum regression, after application of four
different normalization strategies, scaling to total spec-
tral area (red solid line), scaling to creatinine (blue dashed
line), Probabilistic Quotient Normalization (PQN) (green
dotted line), and scaling to TSP (yellow dashed-dotted
line) for (a) the urinary AKI and (b) the plasma AKI
data set. The right column shows the number of features
included in the respective classification models in Venn
diagrams. The corresponding models were built by aver-
aging over all models of the outer CV loop.
tatively to D-glucuronic acid as well as an unknown
metabolite. Other important buckets with large posi-
tive regression weights comprised propofol-glucuronide, 4-
hydroxy-propofol-1-OH-D-glucuronide, isobutyrylglycine,
broad protein signals, and probably 2-oxoisovaleric acid,
indoxyl sulfate, as well as unidentified metabolites. Buck-
ets with large negative regression weights correspond
to a superposition of carnitine and 4-hydroxy-propofol-
4-OH-D-glucuronide, N-acetyl-L-glutamine, and proba-
bly 4-hydroxyphenylacetic acid, as well as unidenti-
fied metabolites. Positive/negative regression coefficients
indicate an up-/down-regulation of the corresponding
metabolite in the AKI in comparison to the non-AKI
group. Consequently, we can report an up-regulation
of exogenous compounds such as glucuronide conjugates
of propofol, an anesthetic agent which had been ad-
ministered during the cardiac surgery and is mainly
metabolized by glucuronidation [Zacharias et al. 2015].
Elevated urinary levels of propofol conjugates in the
AKI group point to a delayed excretion of exoge-
nous compounds caused by reduced glomerular filtra-
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tion or prolonged administration [Zacharias et al. 2013a,
Zacharias et al. 2015]. Higher absolute concentrations
of propofol-glucuronide (p-value = 0.02) have already
been reported for the 24 h urine NMR fingerprints in
[Zacharias et al. 2015]. An up-regulation of carnitine in
the non-AKI group is indicated by its large negative re-
gression weight. This observation has already been re-
ported in [Zacharias et al. 2013a], where an up-regulation
of carnitine, whose main function is the transport of
long-chain fatty acids into the mitochondria for subse-
quent beta-oxidation [Arduini et al. 2008], in the non-
AKI group has been discussed as a successful protective
response against ischemic injury.
Also, logistic zero-sum regression returned the same
predictions for all patients regardless of the applied nor-
malization strategy, summarized in Figure 5, as well as
in Supplementary Figure S3. Furthermore, the zero-sum
constraint did not compromise predictive performance for
the urinary and plasma AKI data set, respectively (Ta-
ble 1, Figures 7a and 7b). AUC values ranged among
the highest for the urinary AKI data set, and yielded the
largest value among all three classification methods in
combination with three different normalization strategies
for the plasma AKI data set. Most importantly, zero-sum
regression reliably identified patients that developed se-
vere AKI (stage 2 and 3, highlighted by yellow dashed
area). Only LASSO on PQN data gave competitive re-
sults. With respect to AUC, zero-sum was still superior.
Moreover, a sample-specific rescaling Γ has no effect on
the corresponding zero-sum prediction probabilities, as il-
lustrated in Figure 6 by the black dotted lines.
4 Discussion
We first pointed out some intrinsic problems in
metabolomics biomarker detection. The identification of
biomarkers strongly depends on the method selected for
scaling the reference profiles. For stand-alone biomarkers,
accordance across scales can be as low as 0%. The same
is true for multivariate biomarker signatures when filter-
ing approaches like filtering by the t-statistics are used,
while wrapping approaches like the LASSO yield some-
what more consistent yet still not scale-independent sig-
natures. More importantly, the prediction of a patient’s
outcome can change depending on the scaling method em-
ployed. In fact, for some cases we could attribute failing
prediction to inappropriate scaling of the raw data. To
overcome this problem we suggest logistic zero-sum re-
gression, which provides a completely scale-independent
analysis. It always selects the same biomarkers, assigns
the same weights to them, and predicts the same out-
come no matter whether the raw data was scaled relative
to total spectral area, creatinine, TSP, any other refer-
ence point, by PQN, or not at all. Furthermore, zero-
sum regression was among the best AKI predictors both
for urinary and plasma fingerprints. Also, the number of
chosen features did not change significantly compared to
other signatures, allowing for transfer of zero-sum signa-
tures into clinical practice.
The interplay of statistical analysis and normal-
ization protocols has been described by several
authors [Hochrein et al. 2015, Kohl et al. 2012,
Gromski et al. 2015, Jauhiainen et al. 2014,
Saccenti 2016]. Proposed strategies to overcome
these issues included the selection of the most “robust”
normalization [Hochrein et al. 2015] or the parallel
application of several normalization strategies and
a subsequent meta analysis of the individual results
[Saccenti 2016]. Clearly, these strategies deal with the
problem, but unlike zero-sum regression do not solve it.
The zero-sum signatures did not identify completely
new biomarkers. In fact, most of the underlying metabo-
lites of the signatures were described before. However, we
believe that zero-sum signatures make better use of these
biomarkers by combining and weighing them differently.
Predictions are no longer confined to a specific normal-
ization protocol but hold in general. Biological interpre-
tation becomes easier as there are fewer user-dependent
choices to make. It is a set of metabolites that hold pre-
dictive information and not their abundance relative to an
arbitrarily chosen reference point. Moreover, signatures
can be validated across studies and tested in different labs
even if scaling protocols do not match or if no scaling is
applied at all. This fact has the potential to greatly en-
hance the reproducibility of clinical trials.
The urinary AKI data set is a good example for data
where a proper normalization cannot replace indepen-
dence of normalization. We believe that this data set
just cannot be normalized properly: varying urine density
precludes TSP normalization, the strong confounding of
spectral areas by D-mannitol signals and by proteinuria
eliminates both normalization to the total spectral area
and PQN, while creatinine excretion is entangled with
kidney function and varies strongly across patients, dis-
qualifying it from use as a common reference. Moreover,
correcting for artifacts like D-mannitol requires that the
existence of an artifact is known for a specific patient.
Interestingly, the LASSO-TSP signature worked sur-
prisingly well in spite of strong variability in urinary den-
sity across patients. Coincidently, however, this signa-
ture had weights adding up to almost (yet not exactly)
zero. LASSO is an algorithm used in artificial intelli-
gence. Here it detected the intrinsic normalization prob-
lems with the TSP-normalization and “intelligently” de-
cided for a scale-independent zero-sum type signature
[Altenbuchinger et al. 2016].
Our zeroSum package can be used on a desktop com-
puter for small data sets and reduced precision. Large
clinical studies with several thousand patients require the
use of an HPC infrastructure. We here offer code that
can be used for such studies.
In conclusion, we provide a high-performance classifica-
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tion framework independent of prior data normalization,
which reduces the number of user-adjustable parameters
and should be ideally suited for the transfer of metabolic
signatures across labs. Furthermore, we expect that the
results presented here also hold for metabolomics data
generated by other methods such as mass spectrometry.
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Table 1: Spectral positions and p-values of the ten most significant NMR buckets for the urinary AKI data set after (a) scaling
to total spectral area, (b) scaling to creatinine, and (c) Probabilistic Quotient Normalization (PQN). The FDR was adjusted
according to the method of Benjamini and Hochberg (B/H). In case more than one compound contributed to one significant
bin, all possibly corresponding molecules are annotated.
(a) scaling to total spectral area
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
2.465 -1.02 -6.59 1.53e-09 7.50e-07 Carnitine/2-Oxoglutaric acid/Glutamine
2.475 -0.98 -6.53 2.14e-09 7.50e-07 Carnitine/Glutamine
2.605 -0.84 -6.31 5.96e-09 1.39e-06 Unknown
2.385 -0.87 -6.22 9.16e-09 1.49e-06 L-pyroglutamic acid/Unknown
2.485 -0.99 -6.19 1.06e-08 1.49e-06 Carnitine/Glutamine/Acetyl-L-carnitine
2.245 -1.01 -6.12 1.46e-08 1.49e-06 Unknown/Acetone
2.365 -0.87 -6.12 1.49e-08 1.49e-06 3-Hydroxyisovaleric acid
2.495 -0.98 -5.86 4.91e-08 4.29e-06 Acetyl-L-carnitine/Glutamine/Unknown
2.625 -0.86 -5.72 9.24e-08 7.18e-06 Acetyl-L-carnitine
3.235 -1.13 -5.68 1.13e-07 7.91e-06 Acetone
(b) scaling to creatinine
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
1.395 0.90 6.71 9.28e-10 5.19e-07 Tranexamic acid
1.375 1.13 6.57 1.80e-09 5.19e-07 Tranexamic acid
1.045 1.24 6.52 2.23e-09 5.19e-07 Tranexamic acid
1.825 0.98 6.18 1.16e-08 1.98e-06 Tranexamic acid
1.025 1.06 6.13 1.42e-08 1.98e-06 Tranexamic acid
1.845 0.98 6.06 1.96e-08 2.29e-06 Tranexamic acid
1.065 1.03 5.92 3.77e-08 3.77e-06 Tranexamic acid
1.355 0.95 5.87 4.72e-08 4.13e-06 Tranexamic acid/2-Hydroxyisobutyric acid
1.055 0.99 5.82 6.10e-08 4.22e-06 Tranexamic acid
1.385 1.01 5.81 6.40e-08 4.22e-06 Tranexamic acid
(c) PQN
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
2.475 -0.52 -6.47 2.92e-09 1.89e-06 Carnitine/Glutamine
2.465 -0.56 -6.34 5.39e-09 1.89e-06 Carnitine/2-Oxoglutaric acid/Glutamine
2.485 -0.54 -5.97 3.13e-08 7.31e-06 Carnitine/Glutamine/Acetyl-L-carnitine
1.395 0.52 5.77 7.84e-08 1.37e-05 Tranexamic acid
2.605 -0.39 -5.36 4.76e-07 6.67e-05 Unknown
2.615 -0.40 -5.16 1.12e-06 1.13e-04 Unknown
1.025 0.67 5.16 1.13e-06 1.13e-04 Tranexamic acid
1.375 0.74 5.12 1.37e-06 1.17e-04 Tranexamic acid
1.045 0.85 5.09 1.50e-06 1.17e-04 Tranexamic acid
2.495 -0.53 -5.05 1.84e-06 1.29e-04 Acetyl-L-carnitine/Glutamine/Unknown
2
Table 2: Spectral positions and p-values of the ten most significant NMR buckets for the plasma AKI data set after (a)
scaling to total spectral area, (b) Probabilistic Quotient Normalization (PQN), and (c) scaling to TSP. The FDR was adjusted
according to the method of Benjamini and Hochberg (B/H). In case more than one compound contributed to one significant
bin, all possibly corresponding molecules are annotated.
(a) scaling to total spectral area
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
7.285 1.37 7.71 2.10e-11 1.47e-08 Propofol-glucuronide/Tryptophan
4.305 1.24 7.57 3.98e-11 1.47e-08 Multiple compounds
3.625 -0.44 -7.28 1.49e-10 3.68e-08 Free EDTA
7.275 0.90 6.94 7.23e-10 1.34e-07 Tryptophan/Propofol-glucuronide
1.165 1.04 6.83 1.18e-09 1.75e-07 4-Hydroxy-propofol-1-OH-D-glucuronide/
Propofol-glucuronide/Isopropanol
4.315 1.28 6.66 2.56e-09 3.15e-07 Multiple compounds
4.295 0.66 6.48 5.57e-09 5.89e-07 Multiple compounds
1.385 0.91 6.35 1.01e-08 9.38e-07 Tranexamic acid
4.015 0.58 6.17 2.16e-08 1.78e-06 Isopropanol/Unknown
3.285 0.47 6.03 4.07e-08 3.01e-06 Myo-inositol/D-glucuronic acid (?)/
Phenylalanine/
4-Hydroxy-propofol-4-OH-D-glucuronide
(b) PQN
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
3.625 -0.57 -8.48 5.88e-13 4.35e-10 Free EDTA
7.285 1.24 7.42 7.91e-11 2.93e-08 Propofol-glucuronide/Tryptophan
4.305 1.11 7.12 3.14e-10 7.75e-08 Multiple compounds
7.275 0.77 6.59 3.48e-09 6.44e-07 Tryptophan/Propofol-glucuronide
1.165 0.92 6.52 4.72e-09 6.99e-07 4-Hydroxy-propofol-1-OH-D-glucuronide/
Propofol-glucuronide/Isopropanol
3.105 -0.23 -6.36 9.40e-09 1.16e-06 CaEDTA2−
4.315 1.15 6.23 1.68e-08 1.77e-06 Multiple compounds
3.335 -0.18 -6.05 3.69e-08 3.41e-06 Unknown/Proline (?)/Tryptophan
3.165 -0.22 -5.97 5.25e-08 4.32e-06 CaEDTA2−
1.385 0.79 5.92 6.61e-08 4.89e-06 Tranexamic acid
(c) scaling to TSP
Spec. pos. [ppm] log 2 FC t-value raw p-value B/H adj. p-value Metabolite
7.285 1.45 7.80 1.40e-11 1.04e-08 Propofol-glucuronide/Tryptophan
4.305 1.32 7.35 1.09e-10 4.05e-08 Multiple compounds
7.275 0.98 6.97 6.15e-10 1.49e-07 Tryptophan/Propofol-glucuronide
1.165 1.12 6.91 8.05e-10 1.49e-07 4-Hydroxy-propofol-1-OH-D-glucuronide/
Propofol-glucuronide/Isopropanol
4.315 1.36 6.61 3.19e-09 4.72e-07 Multiple compounds
2.815 0.38 6.44 6.83e-09 8.43e-07 Unknown
3.285 0.55 6.39 8.35e-09 8.83e-07 Myo-inositol/D-glucuronic acid (?)/
Phenylalanine/
4-Hydroxy-propofol-4-OH-D-glucuronide
3.625 -0.36 -6.32 1.13e-08 1.05e-06 Free EDTA
2.765 0.28 6.29 1.29e-08 1.06e-06 Unknown
1.385 0.99 6.23 1.71e-08 1.26e-06 Tranexamic acid
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Figure 1: − log10(p-values) of moderated t-test analysis comparing healthy versus diseased patients for the plasma AKI data
set after preprocessing with three different normalization methods, i.e., (a) scaling to equal total spectral area, (b) PQN, or
(c) scaling to TSP, respectively, plotted versus the ppm regions of the corresponding NMR features (upper figure). A red line
marks the significance level for Benjamini-Hochberg (B/H) adjusted p-values below 0.01, corresponding to a false discovery
rate (FDR) below 1%. All NMR features with a B/H-adjusted p-value below 0.01 are represented as red dots. The lower
figures, (e - h), show the corresponding log 2(fold-changes) (log 2 FC) versus the ppm regions of the corresponding NMR
features. log 2 FCs were calculated as AKI minus non-AKI, thus positive log 2 FCs correspond to higher values in AKI than
in non-AKI.
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Figure 2: The plasma AKI data set: Receiver operating characteristic (ROC) curves for two classification approaches, (a) SVM
in combination with t-test based feature filtering, and (b) LASSO, after application of three different normalization strategies:
scaling to total spectral area (red solid line), Probabilistic Quotient Normalization (PQN) (green dotted line), and scaling
to TSP (yellow dashed-dotted line). The bottom row shows the number of features included in the respective classification
models in Venn diagrams. The corresponding models were built by averaging over all models of the outer CV loop.
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Figure 3: Classification results patient by patient for the plasma AKI data set: The row “patient outcome” shows patients that
did not develop AKI in blue, patients that developed AKI in red, while patients that developed severe AKI (AKIN stage 2 and
3) are further highlighted by the yellow dashed region. Above we give predictions for the onset of AKI for f-SVM, LASSO,
and zero-sum, using normalization strategies as indicated in brackets. AKI predictions are shown in red (AKIN stages 1 to
3), while patients predicted as non-AKI are shown in blue.
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